---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002849"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T10:00:33.702200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook

## Summary
- Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).
- Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.
- FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).
- Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).
- On track for 30% operating margin by 2027; announces $700M net savings program.

## SEC filing metadata
- accession: 0001171843-25-002849
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/0001171843-25-002849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/f8k_050725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002849
- JSON: https://secwatch.observer/filing/0001171843-25-002849.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.